CAL
RARX

Capital Analysts LLC’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Capital Analysts LLC’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-300
Closed -$7K – 746
2019
Q3 		$7K Buy
+300
New +$8.89K ﹤0.01% 589

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Analysts LLC's RARX Position: Q4 2019 in Review

Capital Analysts LLC sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 300 shares — an estimated $7K sold.

Capital Analysts LLC first reported a position in RARX in Q3 2019 and held it in 1 quarter. The position peaked at $7K in Q3 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

  • Capital Analysts LLC reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Capital Analysts LLC sold 300 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $7K.
  • Capital Analysts LLC first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 1 quarter.
  • Capital Analysts LLC's Ra Pharmaceuticals, Inc. Common Stock position peaked at $7K in Q3 2019.
  • 146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Capital Analysts LLC's 13F filing for Q4 2019, filed 12 Feb 2020.